Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Connection

Search Results to Konstantinos Arnaoutakis

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Arnaoutakis, Konstantinos

Item TypeName
Grant A Randomized, Open-label, Phase III Study to Evaluate the Efficacy and safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients
Grant Pfizer A7471009, A Randomized Double Blind Phase 3 Efficacy and Safety Study of PF-00299804 versus Erlotinib for the Treatment of Advanced Non-Small C
Grant Phase III, Randomized, Open-Label Study of the Efficacy and Safety of PF-02341066 Versus Standard of Care Chemotherapy (Pemetrexed or Docetaxel) in Pa
Grant PHASE 3 Study EVAL EFFICACY AND SAFETY OF MPDL32 80A (IN COMBINATION W CARBOPLATIN+PACLITAXEL OR MPDL3280A IN COMBO W CARBO+NAB -PACLITAXEL VERSUS CARBO+NAB-PACLITAXEL IN CHEMO-NAÏVE PTS W STAGE 4 SQUAMOUS NON SMALL CELL LUNG CANCER
Grant A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer (CheckMate 817, CHECKpoint pathway and nivoluMAb clinical Trial Evaluation)
Grant Phase 2, Open-Label Single Arm Study of the Efficacy and Safety of PF-02341066 in
Grant A Randomized, Open-label, Phase III Study to Evaluate the Efficacy and safety of
Grant A Randomized, Open-label, Phase III Study to Evaluate the Efficacy and safety of
Grant Phase 2, Open-Label Single Arm Study of the Efficacy and Safety of PF-02341066 in
Grant Pfizer A7471009, A Randomized Double Blind Phase 3 Efficacy and Safety Study of PF-00299804 versus Erlotinib for the Treatment of Advanced Non-Small C
Grant Phase III, Randomized, Open-Label Study of the Efficacy and Safety of PF-02341066 Versus Standard of Care Chemotherapy (Pemetrexed or Docetaxel) in Pa
Grant A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamabin Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-301)
Grant A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamabin Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-301)

Search Criteria
  • Safety